← back to search

Sabin Nsanzimana

Brown University · US
Area of research
Infectious Diseases · Hepatology
Research interest
Research interests include Medicine, Psychological intervention, Public health, Sofosbuvir, Hepatitis C virus, and Regimen.
h-index
citations
1,545
works
24
NIH funding
primary concept
email

Recent publications

Marburg Virus Disease in Rwanda, 2024 — Public Health and Clinical Responses
New England Journal of Medicine 2025cited by 11position: firstdoi
Refining early detection of Marburg Virus Disease (MVD) in Rwanda: Leveraging predictive symptom clusters to enhance case definitions
International Journal of Infectious Diseases 2025cited by 10position: middledoi
SMS-based digital health intervention in Rwanda's home-based care program for remote management of COVID-19 cases and contacts: A qualitative study of sustainability and scalability
Frontiers in Digital Health 2023cited by 14position: middledoi
Advancing detection and response capacities for emerging and re-emerging pathogens in Africa
The Lancet Infectious Diseases 2022cited by 33position: middledoi
Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign
The Journal of Infectious Diseases 2022cited by 28position: middledoi
Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial
˜The œLancet. Gastroenterology & hepatology 2022cited by 18position: middledoi
Expert considerations and consensus for using dogs to detect human SARS-CoV-2-infections
Frontiers in Medicine 2022cited by 16position: middledoi
Results of the Kigali Imbereheza Project: A 2-Arm Individually Randomized Trial of TI-CBT Enhanced to Address ART Adherence and Mental Health for Rwandan Youth Living With HIV
JAIDS Journal of Acquired Immune Deficiency Syndromes 2022cited by 15position: middledoi
Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial
˜The œLancet. Gastroenterology & hepatology 2022cited by 11position: middledoi
Contact Tracing and the COVID-19 Response in Africa: Best Practices, Key Challenges, and Lessons Learned from Nigeria, Rwanda, South Africa, and Uganda
American Journal of Tropical Medicine and Hygiene 2021cited by 105position: middledoi
Genomic sequencing of SARS-CoV-2 in Rwanda reveals the importance of incoming travelers on lineage diversity
Nature Communications 2021cited by 37position: middledoi
From Easing Lockdowns to Scaling Up Community-based Coronavirus Disease 2019 Screening, Testing, and Contact Tracing in Africa—Shared Approaches, Innovations, and Challenges to Minimize Morbidity and Mortality
Clinical Infectious Diseases 2020cited by 65position: middledoi
HIV infection and engagement in HIV care cascade among men who have sex with men and transgender women in Kigali, Rwanda: a cross‐sectional study
Journal of the International AIDS Society 2020cited by 50position: middledoi
Improved quality of life following direct‐acting antiviral treatment for chronic hepatitis C infection in Rwanda: Results from a clinical trial in sub‐Saharan Africa (the SHARED study)
Journal of Viral Hepatitis 2020cited by 4position: middledoi
Applying the Exploration Preparation Implementation Sustainment (EPIS) Framework to the Kigali Imbereheza Project for Rwandan Adolescents Living With HIV
JAIDS Journal of Acquired Immune Deficiency Syndromes 2019cited by 31position: lastdoi
Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir–sofosbuvir (SHARED): a single-arm trial
˜The œLancet. Gastroenterology & hepatology 2018cited by 86position: middledoi
Influence of supply-side factors on voluntary medical male circumcision costs in Kenya, Rwanda, South Africa, and Zambia
PLoS ONE 2018cited by 17position: middledoi
Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis
The Lancet HIV 2017cited by 68position: middledoi
Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration
EBioMedicine 2017cited by 50position: middledoi
Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis
PLoS Medicine 2016cited by 532position: middledoi
Implementation and Operational Research: Evolution of Couples' Voluntary Counseling and Testing for HIV in Rwanda: From Research to Public Health Practice
JAIDS Journal of Acquired Immune Deficiency Syndromes 2016cited by 39position: middledoi
Improving health outcomes through concurrent HIV program scale-up and health system development in Rwanda: 20 years of experience
BMC Medicine 2015cited by 45position: firstdoi
The mental health of HIV-positive adolescents
The Lancet Psychiatry 2015cited by 17position: lastdoi
Rwanda 20 years on: investing in life
The Lancet 2014cited by 243position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 5 papers (2018–2025)Philip Grant · Stanford University4 papers (2018–2022) · 4 papers (2016–2025)Jean B. Nachega · University of Pittsburgh4 papers (2016–2022)Etienne Karita · Emory University4 papers (2015–2022) · 4 papers (2020–2025)Neil Gupta · Makerere University4 papers (2018–2022) · 4 papers (2018–2022)Edward J. Mills · Sheffield Teaching Hospitals NHS Foundation Trust4 papers (2015–2022) · 3 papers (2018–2022)Jeanine Condo · Tulane University3 papers (2018–2021) · 3 papers (2020–2022)Grégory Camus · Vir Biotechnology (Switzerland)3 papers (2018–2022) · 3 papers (2018–2022)Susan Allen · Emory University3 papers (2016–2022) · 3 papers (2018–2022)Alimuddin Zumla · Semmelweis University3 papers (2020–2022) · 3 papers (2020–2022) · 3 papers (2015–2022) · 3 papers (2015–2022)